Elisity, founded in 2019, makes software that limits how attackers and ransomware move through corporate networks. Hospitals and healthcare firms are among its main customers, and the company reports more than 100 deployments, including a growing number of Fortune 500 clients. IonQ says Elisity's revenue and customer base doubled year over year. Investors reacted sharply: IonQ shares fell roughly 9 to 10 percent after the announcement, as analysts flagged dilution from the new stock issuance. The public announcement did not disclose Elisity's standalone revenue or profitability, and the final share count will not be known until closing.
The deal combines IonQ's post-quantum cryptography and quantum key distribution products with Elisity's Zero Trust platform. IonQ chairman and CEO Niccolo de Masi framed the purchase as a response to AI-driven attacks and to "Q-Day," the risk that quantum computers could eventually break current encryption. It also follows two executive orders President Trump signed in June 2026, and IonQ has cited a White House directive requiring federal agencies to move to post-quantum cryptography. For attorneys, watch the regulatory review that gates the fourth-quarter closing, the final share count set at closing, and the earnout terms, which will determine how much of the $1.3 billion is actually paid. The deal also extends IonQ's acquisition run, which already includes SkyWater Technology and Oxford Ionics.